Aytu Bioscience, Inc. Announces Hiring of Matthew Phillips as Executive Vice President of Commercial Operations
November 12, 2019 at 08:15 am
Share
Aytu BioScience, Inc. announced the hiring of Matthew Phillips as the company's Executive Vice President of Commercial Operations. Mr. Phillips' hiring became effective November 8, 2019 following the recently announced acquisition of a portfolio of six prescription products from Cerecor, Inc. (the 'Commercial Portfolio') and the accompanying commercial team supporting the products' growth. Mr. Phillips was responsible for leading the growth of the Commercial Portfolio as the Chief Commercial Officer at Cerecor, Inc. and its predecessor company Zylera Pharmaceuticals. In his role as Executive Vice President, Mr. Phillips will lead Aytu BioScience's commercial operations, inclusive of sales, national accounts, trade management, specialty distribution, supply chain and commercial logistics. He will report to Josh Disbrow, Aytu's Chairman and Chief Executive Officer.
Aytu BioPharma, Inc. is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Companyâs Rx segment consists of prescription pharmaceutical products and the Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Companyâs prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD); Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions; and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Its Consumer Health Segment addresses a range of common conditions.
AYTU BIOPHARMA, INC. 
